What is the core objective of the collaboration between Takeda (NYSE:TAK) and the Indonesian Government?

The collaboration aims to strengthen Indonesia's plasma ecosystem and ensure equitable access to lifesaving plasma-derived medicinal products (PDMPs). The initiative seeks to build local capabilities in plasma collection and explore the feasibility of domestic biopharmaceutical manufacturing.

How much is Takeda (NYSE:TAK) investing in the Indonesian initiative?

Takeda (NYSE:TAK) committed an initial investment of up to $30 million to launch a two-year pilot program. This capital will fund the establishment of plasma donation centers as part of a potential national network.

When will the first plasma donation center open in Indonesia?

Takeda (NYSE:TAK) expects the first plasma donation center in Indonesia to open in 2027. These locations will be operated as part of Takeda’s global BioLife plasma center network.

What happens to the plasma collected in Indonesia during the pilot phase?

Until a local manufacturing facility is established, plasma collected in Indonesia will be fractionated within Takeda’s existing global manufacturing network. Takeda (NYSE:TAK) has committed to prioritizing Indonesia's domestic needs for PDMPs throughout this process.

What long-term potential does this project hold for Indonesia?

The initiative aims to position Indonesia as a regional hub for plasma science and advanced manufacturing within the ASEAN region. Beyond product supply, the collaboration focuses on technology transfer, workforce training, and the creation of highly skilled jobs in the biopharmaceutical sector.

Image for illustrative purposes only. Not a real photo.

Takeda announces $30 million Indonesian plasma collaboration

Written by Isaac FrancisPublished Jul 13, 2026, 7:53 AM

Takeda (NYSE:TAK) will invest up to $30 million in a multi-phased initiative to strengthen Indonesia’s plasma-derived medicinal product (PDMP) ecosystem.
The Ministry of Health of the Republic of Indonesia granted Takeda a plasma fractionation license to facilitate local collection and processing.
The company plans to launch a national plasma donation network pilot, with the first center expected to open in 2027.

Takeda (NYSE:TAK) and the Indonesian Government announced a landmark multi-year collaboration to enhance domestic health resilience and access to lifesaving therapies.

The initiative centers on the sustainable collection of high-quality plasma and the eventual manufacturing of plasma-derived medicinal products (PDMPs) within the country.

Takeda’s initial $30 million investment funds a two-year pilot program designed to establish plasma donation centers.

These centers will be integrated into Takeda’s existing BioLife network and adhere to international regulatory standards.

While the feasibility of a local manufacturing facility is under assessment, plasma collected during the pilot will be processed through Takeda’s global manufacturing network, prioritizing Indonesia's domestic supply needs.

The company anticipates this project will serve as a regional hub for plasma science and biopharmaceutical innovation.

Takeda announces $30 million Indonesian plasma collaboration

Frequently asked questions

Assets related to this article